Forum Topic News
  • Conversation: Indivior's RECOVER™ Study Finds Three-quarters of Patients with Moderate to Severe Opioid Use Disorder Who Received 12 monthly Injections of SUBLOCADE™ (Buprenorphine Extended-Release) Injection were Abstinent from Illicit Opioids One Year Later

    • April 5, 2019 7:34 PM BST
    • Indivior's RECOVER™ Study Finds Three-quarters of Patients with Moderate to Severe Opioid Use Disorder Who Received 12 monthly I...

      Indivior PLC today announced data from two studies evaluating efficacy and long-term safety of once-monthly SUBLOCADE™ (buprenorphine extended-release) injection for subcutaneous use (CIII) for the treatment of moderate to severe opioid use disorder.
      • The RECOVER™ study found that 75 percent of patients who had received 12 once-monthly doses of SUBLOCADE in a Phase 3 clinical trial were abstinent from illicit opioids for a year after the study ended. In this observational study, abstinence was defined as self-report confirmed by urine drug screen. Some patients had the option to continue SUBLOCADE following the clinical trial or chose to continue another form of medication-assisted treatment during the RECOVER study period.
      • An 18-month safety study among SUBLOCADE-treated patients reported no new safety issues.
      SUBLOCADE is approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe OUD in adult patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment for a minimum of seven days.
      Read more: https://prn.to/2TUZTFT

Add Reputation

Do you want to add reputation for this member by this post?

or cancel